Niven R. Narain

Berg LLC operates as a biopharmaceutical company, which focuses on taking a bold back to biology approach to therapeutic discovery using its Interrogative Biology platform. Its therapeutics include cancer metabolism and BPM 31510, chemotherapy induced alopecia and BPM 315453, neurology-discovery program, and metabolic disease-discovery program. The company was founded by Carl Edwin Berg, Mitch Gray, and Niven R. Narain in 2006 and is headquartered in Framingham, MA.

BPGbio Inc is a clinical stage biopharma and diagnostics company that focuses on oncology, neurology, and rare diseases. BPGbio's approach is underpinned by NAI, its proprietary interrogative biology platform, protected by over 400 US and international patents, the world's largest clinically annotated non-governmental biobank, and exclusive access to the most powerful supercomputer in the world. The private company is based in Framingham, MA, and has subsidiaries in the United States. The company has a portfolio of AI-developed therapeutics, including several in late-stage development. The CEO of the company is Niven R. Narain.